https://www.selleckchem.com/pr....oducts/Trichostatin-
. Two tumor beds (12.5%) experienced radiation brain changes one had grade two and the other grade three. No surgical adverse events occurred. Conclusion In this single-arm precommercial study, R+STaRT demonstrated excellent safety and LC in this cohort. The device has recently received FDA clearance for use in newly diagnosed and recurrent brain metastasis, and randomized clinical trials vs. standard of care treatments in both settings are scheduled to open in 2020.We report an unusual case of a 76-year-old woman with a necrotic
Like
Comment
Share
